ANI Pharmaceuticals, Inc. (ANIP)
71.47
+0.41
(+0.58%)
USD |
NASDAQ |
Nov 13, 16:00
71.47
0.00 (0.00%)
After-Hours: 19:59
ANI Pharmaceuticals Gross Profit Margin (Quarterly) : 54.92% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 54.92% |
| June 30, 2026 | 54.97% |
| March 31, 2026 | 51.78% |
| December 31, 2025 | 50.26% |
| September 30, 2025 | 49.07% |
| June 30, 2025 | 53.69% |
| March 31, 2025 | 51.34% |
| December 31, 2024 | 46.02% |
| September 30, 2024 | 46.86% |
| June 30, 2024 | 47.56% |
| March 31, 2024 | 53.55% |
| December 31, 2023 | 47.88% |
| September 30, 2023 | 51.98% |
| June 30, 2023 | 51.12% |
| March 31, 2023 | 50.92% |
| December 31, 2022 | 46.08% |
| September 30, 2022 | 43.86% |
| June 30, 2022 | 33.58% |
| March 31, 2022 | 24.27% |
| December 31, 2021 | 21.91% |
| September 30, 2021 | 31.31% |
| June 30, 2021 | 30.82% |
| March 31, 2021 | 43.36% |
| December 31, 2020 | 38.10% |
| September 30, 2020 | 40.59% |
| Date | Value |
|---|---|
| June 30, 2020 | 34.20% |
| March 31, 2020 | 33.73% |
| December 31, 2019 | 52.55% |
| September 30, 2019 | 52.32% |
| June 30, 2019 | 53.82% |
| March 31, 2019 | 41.71% |
| December 31, 2018 | 49.55% |
| September 30, 2018 | 52.36% |
| June 30, 2018 | 47.31% |
| March 31, 2018 | 37.85% |
| December 31, 2017 | 41.91% |
| September 30, 2017 | 41.50% |
| June 30, 2017 | 36.95% |
| March 31, 2017 | 36.96% |
| December 31, 2016 | 40.54% |
| September 30, 2016 | 41.25% |
| June 30, 2016 | 43.35% |
| March 31, 2016 | 60.99% |
| December 31, 2015 | 68.67% |
| September 30, 2015 | 73.43% |
| June 30, 2015 | 76.66% |
| March 31, 2015 | 78.31% |
| December 31, 2014 | 76.45% |
| September 30, 2014 | 75.57% |
| June 30, 2014 | 57.53% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Eli Lilly & Co. | 83.88% |
| Supernus Pharmaceuticals, Inc. | 77.67% |
| Ocular Therapeutix, Inc. | 79.17% |
| Corcept Therapeutics, Inc. | 98.65% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 19.09% |
| Return on Assets | 7.40% |
| Return on Invested Capital | 9.14% |
| Profit Margin (Quarterly) | 11.25% |
| Operating Margin (Quarterly) | 17.83% |
| Return on Net Operating Assets | 10.07% |